Genitourinary Syndrome of Menopause: Symptoms, Diagnosis, and Treatment Options

What Is Genitourinary Syndrome of Menopause?

Genitourinary syndrome of menopause is a broad clinical term adopted in 2014 by the International Society for the Study of Women's Sexual Health (ISSWSH) and the Menopause Society (formerly NAMS) to replace the older, narrower labels "vulvovaginal atrophy" and "atrophic vaginitis." The syndrome captures every low-estrogen change affecting the vulva, vagina, urethra, and bladder. Symptoms include vaginal dryness, burning, and itching; dyspareunia; reduced vaginal lubrication during arousal; urinary urgency, frequency, and recurrent urinary tract infections; and a sensation of pressure or incomplete emptying.

Estrogen and androgen receptors are dense throughout the lower genitourinary tract. When ovarian estradiol production drops below roughly 30 pg/mL at menopause, vaginal epithelium thins, glycogen stores fall, the Lactobacillus-dominant microbiome shifts, vaginal pH rises from 3.8, 4.5 toward 6, 7, and submucosal collagen is lost. These changes are measurable on a maturation index at the time of a pelvic exam: fewer superficial cells, more parabasal cells. Without intervention, the process continues indefinitely.

A 2019 survey of 3,768 postmenopausal women published by The Menopause Society found that 84% reported at least one moderate-to-severe GSM symptom, yet fewer than 25% had discussed it with a clinician [1]. That gap reflects persistent cultural silence around menopause-related sexual symptoms, not a shortage of effective treatments.

How GSM Causes Dyspareunia and Sexual Pain

Dyspareunia, pain with intercourse, is among the most reported GSM symptoms and one of the most undertreated. The mechanism is direct: thinned, less elastic vaginal epithelium tears more easily with friction, and reduced lubrication amplifies the shear force. Introital (entry) pain is most common, but deeper dyspareunia also occurs when the vaginal canal shortens and loses distensibility.

ACOG Practice Bulletin 141 states, "vaginal dryness and dyspareunia are the predominant symptoms of vulvovaginal atrophy and are reported in approximately 50 percent of postmenopausal women" [2]. Left untreated, recurrent pain during intercourse may trigger secondary vaginismus, a reflexive pelvic-floor muscle contraction that anticipates and worsens pain.

Distinguishing GSM-driven dyspareunia from other causes matters clinically. Provoked vestibulodynia, lichen sclerosus, pelvic inflammatory disease, endometriosis, and interstitial cystitis all present with some version of pelvic or sexual pain. A systematic pelvic exam, vaginal pH measurement, wet mount, and sometimes vulvar biopsy help separate these conditions. Treating only the GSM component when lichen sclerosus is co-present, for example, produces partial relief at best.

Clinicians at HealthRX assess dyspareunia using a structured pain mapping protocol, asking patients to localize pain as entry, mid-vaginal, or deep, rate it on a 0, 10 numeric scale, and note whether pain persists after intercourse ends. This granular picture guides whether vaginal estrogen alone, combined pelvic floor physical therapy, or a referral to a specialist is the right next step.

Vaginismus: When Pelvic Floor Muscle Spasm Becomes the Primary Problem

Vaginismus describes involuntary contraction of the pelvic floor muscles, specifically the bulbocavernosus and puborectalis, in response to attempted vaginal penetration. It may be lifelong (primary) or acquired after a period of comfortable penetration (secondary). Secondary vaginismus develops in some women with GSM as the nervous system learns to brace against anticipated pain.

ISSWSH guidelines classify vaginismus under genito-pelvic pain/penetration disorder (GPPPD), the term used in DSM-5 [3]. Treatment is behavioral and physical rather than pharmacological. Pelvic floor physical therapy, with graded vaginal dilator programs, biofeedback, and manual myofascial release, resolves or substantially improves secondary vaginismus in most cases when combined with effective GSM management. One systematic review in the Journal of Sexual Medicine found pelvic floor physical therapy produced clinically meaningful pain reduction in 80% of women with GPPPD across 21 trials [4].

Overnight use of a vaginal dilator while also using vaginal estrogen cream can accelerate both tissue restoration and muscle retraining. Sessions with a pelvic floor physical therapist typically range from 6 to 12 visits over 2 to 4 months.

Hypoactive Sexual Desire Disorder (HSDD) and Its Relationship to GSM

HSDD is defined as persistently low or absent sexual desire that causes personal distress or interpersonal difficulty, not explained by another medical condition, medication, or lack of an appropriate stimulus. GSM and HSDD frequently coexist but are distinct diagnoses requiring separate treatment strategies.

The ISSWSH defines HSDD as requiring distress by the patient herself: a woman who feels no particular distress about reduced desire does not meet diagnostic criteria [5]. Prevalence estimates range from 10% in premenopausal women to 12 to 14% in postmenopausal women, with rates rising further in surgically menopausal women who lose both ovarian estrogen and testosterone abruptly.

Two FDA-approved pharmacological options exist for HSDD. Flibanserin (Addyi) 100 mg taken nightly is approved for premenopausal women with acquired, generalized HSDD. The VIOLET trial (N=949) showed flibanserin increased satisfying sexual events (SSEs) by 0.5 per month above placebo at 24 weeks, with a statistically significant improvement in desire score (P<0.001) [6]. Bremelanotide (Vyleesi) 1.75 mg subcutaneous injection, taken 45 minutes before anticipated sexual activity, is also approved for premenopausal HSDD; the RECONNECT trials (N=1,247) showed a mean 0.3-point improvement in desire domain score vs. placebo (P<0.05) [7].

Neither drug is formally approved for postmenopausal HSDD. Off-label use of transdermal testosterone is common in this population and is supported by the APHRODITE trial (N=814), in which testosterone patch 300 mcg twice weekly produced 1.56 additional SSEs per 4-week period vs. 0.73 with placebo (P<0.001) in surgically menopausal women not on oral estrogen [8]. The Endocrine Society 2019 guideline recommends considering testosterone therapy for postmenopausal HSDD when other causes have been excluded, though no testosterone product is currently FDA-approved for women in the United States [9].

Treating co-existing GSM often improves desire secondarily. Pain during sex is a potent desire suppressant; remove the pain, and desire may return. Some women, however, have both conditions independently and need both treatment tracks.

Female Orgasmic Disorder: When Orgasm Is Delayed, Reduced, or Absent

Female orgasmic disorder (FOD) is diagnosed when orgasm is markedly delayed, infrequent, or absent on most sexual occasions, and the woman finds this personally distressing. Estimates suggest FOD affects 10 to 15% of women across the lifespan, with prevalence increasing after menopause [10].

Estrogen plays a role in clitoral and vaginal smooth muscle sensitivity. When estrogen drops, clitoral engorgement may be reduced, nerve conduction in genital tissue may slow, and the orgasm threshold may rise. Antidepressants, particularly SSRIs and SNRIs, are a common iatrogenic cause; SSRIs delay or block orgasm in up to 30 to 40% of users [11].

No FDA-approved pharmacotherapy targets FOD specifically. Treatment is multimodal. Directed masturbation programs, cognitive behavioral therapy, and sex therapy have the strongest evidence base. For women whose FOD is clearly estrogen-mediated and tied to GSM, vaginal estrogen may partially restore genital sensitivity. Phosphodiesterase type 5 inhibitors, studied off-label in women, have not demonstrated consistent benefit in randomized trials. A small but notable exception involves women with SSRI-induced orgasmic dysfunction, where sildenafil 50 mg showed benefit in a single-center RCT (N=98; P<0.05) [12]. Those data are preliminary and require replication.

FDA-Approved Treatments for GSM: A Practical Overview

Non-Hormonal First-Line Options

Non-hormonal vaginal moisturizers, applied 3, 5 times per week to the vaginal walls (not just before sex), maintain hydration and may reduce pH modestly. Products containing hyaluronic acid, polycarbophil, or carboxymethylcellulose are preferred. Lubricants, water-based or silicone-based, are used at every sexual encounter to reduce friction. Neither moisturizers nor lubricants reverse tissue atrophy; they address symptoms only.

Low-Dose Vaginal Estrogen

Low-dose vaginal estrogen is the standard of care for moderate-to-severe GSM in women without a contraindication to estrogen. Available forms include:

• Vaginal estradiol cream (Estrace): 0.5 g nightly for 2 weeks, then twice weekly
• Vaginal estradiol tablet (Vagifem / Yuvafem): 10 mcg nightly for 2 weeks, then twice weekly
• Vaginal estradiol ring (Estring): 2 mg released over 90 days
• Vaginal conjugated estrogen cream (Premarin): 0.5 g nightly for 21 days, off 7 days

At these doses, serum estradiol remains within the normal postmenopausal range (<20 pg/mL) for tablets and the ring. The Menopause Society 2023 position statement notes that "low-dose vaginal estrogen preparations are safe and effective for the genitourinary syndrome of menopause and do not require concurrent use of a progestogen for endometrial protection" [13].

Prasterone (Intrarosa)

Prasterone is a vaginal insert containing 6.5 mg of dehydroepiandrosterone (DHEA), a precursor converted locally to both estradiol and testosterone in vaginal tissue. Used nightly, it improves vaginal dryness, dyspareunia, and maturation index. The AMETHYST trial (N=464) demonstrated a significant improvement in the parabasal cell percentage, vaginal pH, and the most bothersome symptom score vs. placebo at 52 weeks (P<0.001) [14]. Because it acts locally, systemic DHEA levels remain within physiologic range.

Ospemifene (Osphena)

Ospemifene is an oral selective estrogen receptor modulator taken as 60 mg once daily with food. It acts as an estrogen agonist in vaginal tissue and an antagonist or neutral agent in breast tissue. In SHORELINE, a 52-week safety study (N=826), ospemifene significantly improved vaginal maturation index and reduced dyspareunia severity vs. placebo, with no increase in endometrial hyperplasia [15]. It carries a class warning for venous thromboembolism and should not be used in women with a history of breast cancer or estrogen-dependent tumors.

Systemic Hormone Therapy

For women who have vasomotor symptoms in addition to GSM, systemic hormone therapy (HT) treats both simultaneously. Options include oral estradiol (0.5 to 2 mg daily), transdermal estradiol patches (0.025 to 0.1 mg/day), gels, and sprays. Women with an intact uterus require concurrent progestogen. The Women's Health Initiative (WHI) Memory Study and subsequent re-analyses confirm the risk-benefit profile of HT is favorable for healthy women under 60 initiating therapy within 10 years of menopause, a principle known as the "timing hypothesis" [16].

Laser and Energy-Based Devices

CO2 fractional laser (MonaLisa Touch) and erbium laser devices have generated interest as office-based options for GSM. However, the FDA issued a 2018 safety communication cautioning against these devices for vaginal "rejuvenation" outside clinical trials, citing limited evidence of efficacy and reports of adverse events including burns [17]. Randomized sham-controlled trials to date show mixed results; a 2021 RCT in JAMA (N=72) found CO2 laser did not significantly outperform vaginal estrogen for dyspareunia over 12 months [18].

When GSM, HSDD, and Orgasmic Disorder Overlap

Many perimenopausal and postmenopausal women present with features of two or three of these conditions simultaneously. A woman with severe dyspareunia from GSM, low desire meeting HSDD criteria, and difficulty reaching orgasm is not uncommon in clinical practice.

The correct clinical approach is to address conditions in order of patient priority and physiologic primacy. GSM should be treated first in most cases because unresolved sexual pain suppresses desire and blocks orgasm. A 2020 study in Menopause (N=512) found that 4 months of vaginal estrogen treatment produced a statistically significant improvement in desire and orgasm scores on the Female Sexual Function Index (FSFI) as secondary endpoints, without any additional HSDD-specific therapy [19]. Residual HSDD after GSM treatment is then addressed with testosterone (off-label) or flibanserin if the patient is premenopausal.

Medication reconciliation matters at every visit. SSRIs, antihypertensives (especially beta-blockers and spironolactone), antihistamines, and opioids all suppress desire, arousal, or orgasm through distinct mechanisms.

Diagnosis: What a Proper GSM Evaluation Includes

A complete GSM evaluation includes:

1. A thorough symptom history using a validated tool such as the Day-to-Day Impact of Vaginal Aging (DIVA) questionnaire or the FSFI.
2. Vaginal pH measurement with pH paper at the lateral vaginal wall (normal postmenopausal GSM: 5, 7).
3. Maturation index via vaginal cytology: the ratio of parabasal, intermediate, and superficial cells.
4. Visual exam of the vulva and vaginal walls noting pallor, petechiae, stenosis, labial resorption, or loss of rugae.
5. Assessment for concurrent conditions: lichen sclerosus, contact dermatitis, pelvic organ prolapse.

Serum FSH and estradiol are helpful to confirm menopause but are not required to diagnose GSM clinically. Hormone panels for HSDD workup should include total and free testosterone, SHBG, prolactin, and thyroid function.

Monitoring Treatment Response

The Menopause Society recommends reassessing symptom burden 4 to 12 weeks after initiating any GSM therapy [13]. Patients should be asked explicitly about change in dryness, pain with intercourse, and urinary symptoms rather than waiting for them to volunteer this information.

For women on vaginal estrogen long-term, annual assessment is appropriate. No mandatory endometrial surveillance is required for low-dose vaginal estrogen formulations, though clinicians should maintain a low threshold for endometrial biopsy if unexpected spotting occurs.

For women on testosterone for HSDD, total testosterone should be checked 4 to 6 weeks after starting therapy. The Endocrine Society recommends targeting a total testosterone level in the normal premenopausal range (20 to 70 ng/dL), not above it, and checking hematocrit and lipids at baseline and after 6 months [9].